Real-time analysis of prostate tumor tissue components based on multimodal high-frequency ultrasound and digital pathological registration using artificial intelligence

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600121108

Enrollment

Unknown

Registered

2026-03-25

Start date

2024-02-05

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Gold Standard:Biopsy Pathology.

Index test:The output label predicted by classification model and cancerous area predicted by segmentation model.

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Adult male; 2. Receive ultrasound-guided prostate biopsy or other ultrasound examination; 3. Targeted lesion can be visualized on ultrasound and data can be saved completely; 4. The biopsy pathology indicates the prostate cancer.

Exclusion criteria

Exclusion criteria: 1. Biopsy specimens of prostate masses cannot be accurately localized; 2. Poor or incomplete ultrasound images; 3. The pathology diagnosis is unclear; 4. Previous surgery, local therapy (ablation), or systemic systemic therapy (radiotherapy, chemotherapy, immunization, or targeted therapy).

Design outcomes

Primary

Measure	Time frame
mean Intersection over Union;Precision;Area under the curve;	—

Secondary

Measure	Time frame
mean pixel accuracy;Recall;pixel accuracy;Dice similarity coefficiency;	—

Countries

China

Contacts

Public ContactMing Xu

The First Affiliated Hospital,Sun Yat-sen University

xuming8@mail.sysu.edu.cn+86 20 8776 5183

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 4, 2026